AliBERT achieves it first successful application in oncology!
A successful proof-of-concept for AliBERT, the first French-language model specialized in the biomedical field. In partnership with a major French Cancer Fighting Institute, Quinten’s datalab team has developed a first concrete use case : the extraction of concepts and structured information from medical reports in oncology. A Natural Language Processing [NLP] task which, until now, has been highly complex, given the technical nature, diversity and specialization of these medical reports.
A machine learning algorithm to identify persons at risk of Gaucher disease using EHR in the United States
Gaucher disease is a rare inherited lysosomal storage disorder (LSD) which mainly leads to hepatosplenomegaly, anemia, thrombocytopenia, bone lesions/symptoms, and neurological impairment. Its progressive clinical manifestations are often highly debilitating, shorten lifespans and are considerably variable.
Quinten Health to attend the first “Life Sciences in the Nordic countries” mission with Bpifrance & Business France
Quinten Health is delighted to announce its participation to the first “Life Sciences in the Nordic countries ” mission launched by Bpifrance and operated with Business France. This is a wonderful recognition and an opportunity to dive into the Danish and Swedish healthcare market ecosystem and address its challenges and opportunities!
“Securing & accelerating clinical development and market access for therapeutic innovations using Real-World disease and care modeling and simulation”
Alexandre Templier, President of Quinten Health, was invited last Thursday by Norbert Nabet (Ziwig Biotech) to take part in a round table organized by E4i. The theme of the round table was innovative therapies related to precision medicine. Alexandre Templier spoke about how real-world data (RWD) is set to revolutionize the clinical development and market […]
Horizon Europe: Quinten Health into More-EUROPA’s project for more RWD
Quinten Health is participating in the More-EUROPA project in the framework of the Horizon Europe program. The latter funds projects aiming to develop “new methods for the effective use of real-life data and/or synthetic data in regulatory decision-making and/or health technology assessment”. With a duration of 5 years, More-Europa [MORE Effective and ethical Use of […]
Quinten Health is now OMOP certified by EHDEN (the European Health Data & Evidence Network Consortium)
Quinten Health is certified by the European Health Data & Evidence Network (EHDEN) Consortium after their fourth and final call ! This certification allows us to be part of the EHDEN Certified SMEs catalogue, to support mapping of health data to the OMOP Common Data Model, and to provide services in the EU ecosystem for […]
Big Data: a new therapeutic option? Part 6: AI-augmented health
From Data to Artificial Intelligence in healthcare Following Part 5: The future of pharma 6) From Data to Artificial Intelligence Big Data will undoubtedly play a central role in the new relationship that Man will soon have with his well-being, his health and his aging process. Beyond the “quantified self” and connected health, which will […]
Big Data: a new therapeutic option? Part 5: The future of pharma
What is the future for the pharmaceutical industry? Following Part 4: Predict or cure? 5) What future for the pharmaceutical industry? This paradigm shift is also one of the ways forward for a pharmaceutical industry whose historical model is undergoing a crisis. Calico (Google) is tackling the challenge of “age and associated diseases” by recruiting […]
Big Data: a new therapeutic option? Part 4: Predict or cure?
Personalized medicine. Predict or cure: do we need to choose? Following Part 3: Data as raw material 4) Personalized medicine: predict or cure – should we choose? Even if it is often written that “personalized medicine is already a reality in some cases“, or that “personalized medicine is within reach“, it is justified to wonder […]
Big Data: a new therapeutic option? Part 3: Data as raw material
Data as an inexhaustible resource, the expert’s raw material Following Part 2: The end of averaging 3) Data: an inexhaustible resource – the expert’s raw material Whether they are in massive amounts, of reduced volume, or of intermediate size, data are always generated with a precise objective (they are then characterised as primary data). They […]
